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The properties of modified biomaterial are gaining more and more importance in drug
delivery systems. Sialic acid (SA) and polysialic acid (PSA) serve as endogenous substances,
which are non-immunogenic and biodegradable. At the same time, SA modification of the
drugs/carriers can enhance the uptake of tumor cell and retention in brain; PSA modifi-
cation can reduce the immunogenicity of the proteins or polypeptides and increase cir-
culation time of the modified drugs/carriers in the blood, thus achieving active targeting
effect. These properties offer a variety of opportunities for applications in drug delivery
systems. This article summarizes the biological functions of SA and PSA and presents the
technologies of SA/PSA modified small molecule drugs, proteins and carriers in drug de-
livery systems.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Nature sialic acid (SA) is constituted structurally by nine-
carbons 3-deoxy-ulosonic acids. This saccharide moiety
attached to carbohydrate chains of glycolipids and glycopro-
teins plays a crucial role in many important biological events
[1]. Interestingly, it has been found that SA is a well-known
ligand for selectin, which is known to have a close relation-
ship with tumor metastases. Owing to its modulation oftical University, No. 103, W
g Pharmaceutical Univer
sevier
University. Production ancellecell interactions among leukocytes, platelets, endothelial
cells and tumor cells, selectin is responsible for tumor
metastasis [2e5]. SA serves as endogenous substances that
can specifically bind to selectin [6e8]. Hence, the application
of SA-modified carriers in cancer targeted therapy has a
certain significance [9].
Polysialic acid (PSA) is a homopolymer of sialic acid in a-2,8
or a-2,9 linkages or a mixture of a-2,8 and a-2,9. PSA consti-
tuted of a-2,8 bond is non-immunogenic and biodegradableenhua Road, Shenyang 110016, China. Tel./fax: þ86 24 23986316.
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peptide. Likewise PSA shows the properties of escaping from
phagocytes and presenting long circulation time in vivo [10,11].
This review summarizes the applications of SA/PSA in tar-
geting carriers construction and briefly discusses their pros-
pects in drug delivery systems.2. Sialic acid, polysialic acid and derivatives
2.1. Sialic acid
In 1957, Blix [1] isolated a substance from the submandibular
gland mucin via a hydrolysis method, which produced a
purple color reaction with Bial’s reagent. He named the sub-
stance as sialic acid (SA). Afterward, people got perfect crys-
talline SA from colostrumand bird’s nest.With the progress of
biological evolution, the amount of SA in vivo also increased,
such as fish, amphibians, reptiles, birds and other vertebrates.
In mammals, SA mainly distributed over the cerebrospinal
fluid and mucus.
SA belongs to a family of neuraminic acid (5-amido-3,5-
dideoxy-D-glycero-D-galacto-nonulosonic acid). In this fam-
ily, there are three main SA derivatives, which are N-acetyl
neuraminic acid (Neu5Ac), N-acetyl neuraminic acid hydrox-
yalkyl (Neu5Gc) and 3-deoxy-D-glycero-D-galacto-nonyl ketose
(KDN) (Fig. 1). The other SA derivatives are further derived
from these.
Each SA carries a unit negative charge, which generates
repulsion or attraction between SA and plasma protein.
Furthermore, the charge will modulate membrane surface
charge density, while the carboxyl groups of SA can regulate
its own pH. The surface charge density and pH coordinately
regulate the transmembrane transport capacity of cell mem-
brane [12].
SA spreads widely over mammalian cell surface, wherein
the surfaces of red blood cells and endothelial cells are highly
sialylated [13]. It has been found that after treated by sialidase,
the lifetime of erythrocytes dropped from the initial 120 days
to just a few hours [14]. In addition, many pathogens employ
SA to camouflage themselves and mask their epitopes, which
inhibits complement activation pathway to reduce immuno-
genicity and thus protect the pathogens from the attacks of
host immune system [15e17].2.2. Polysialic acid
Polysialic acid (PSA) was first found in E. coli (Escherichia coli) K-
1 and K-235 by Barry [18]. Subsequent studies have discovered
that PSA was one of the ingredients of bacterial capsularFig. 1 e The structumaterials, such as Neisseria miningitidis B, Salmonella toucra 048
and Citrobacter freundii 05, etc. The structure of PSAwas shown
in Fig. 2.
In vertebrates, PSA can attach to the neural adhesion
molecule (NCAM), with its fragments connecting to the
asparagine at Ig5 of NCAM [19]. PSA can attenuate NCAMeN-
CAM interaction and facilitate cell migration and nerve
regeneration. Accordingly, Polysialylated NCAM exists abun-
dantly in the embryo brain. But for the brain tissue of adults,
PSA only appears in the hippocampus and olfactory bulb with
continuous growth ability [20].
Polycondensation of SA occurs between hydroxyl groups at
its 2 and 8 positions and makes the constructed PSA more
stable [21]. The study also found that PSA showed excellent
water solubility, low viscosity, good biocompatibility and
degradation in vivo [22].
PSA has been found in various tumors including small cell
and non-small cell lung carcinomas, rhabdomyosarcoma,
multiple myeloma, neuroblastoma, andWilms tumor etc [20].
Study [23] found patients with extensive rhabdomyosarcoma
showed a high level of PSA-NCAM, while patients had a lesser
amount after chemotherapy. They concluded that the pres-
ence of PSA on the tumor cells reduced adhesion of NCAM,
and enhanced cell motility, thus allowing the tumor cells that
expressed PSA to deviate from the primary tumor and format
metastases. In another study [24], small cell lung carcinoma
cells expressing different amounts of PSA were isolated from
H69 cell line. After subcutaneous inoculation with nude mice,
tumor cells that express PSA produced more intracutaneous
metastasis than tumor cells poorly expressing PSA. Suzuki [20]
et al. reported among 44 patients with astrocytoma examined,
30 cases were NCAM-positive, of which nine cases PSA were
detected, interestingly the nine cases had strong diffusion
ability, revealing that PSA closely correlated with tumor in-
vasion. Therefore, PSA plays an important role in tumor in-
vasion and recurrence.2.3. Ganglioside
Ganglioside is widely used as a SA derivative, which is quite
rich in the brain. It cannot only promotes nerve cell differen-
tiation, growth and synaptic formation, but also takes part in
regulation of neural plasticity and functional recovery after
brain injury. Among gangliosides, monosialylganglioside
(GM1) have drawn the most interest by far.
GM1 is mainly distributed over the central nervous system,
which promotes the neuronal proliferation, neurotrophy,
anti-excitatory nerve repair and other multiple effects. GM1
can be used clinically for the treatment of central nervous
system injury diseases, such as stroke, traumatic brain injury,re of sialic acid.
Fig. 2 e The structure of polysialic acid, a-2,8-(A), a-2,9-(B).
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athy, and peripheral nerve disease.
In addition, other current common gangliosides are GM2,
GM3, GD1, GD2 and GD3, wherein GM contains mono sialic
acid group, GD represents double, GT represents triple and, GQ
means quadruple. All glycolipid contain two parts: a common
nucleus-ceramide (Cer) that constitutes a hydrophobic “tail”,
inserts in the membrane lipid bilayer; oligosaccharide sugar
chain as a hydrophilic “head”, mainly includes the D-glucose
(Glc), D-galactose (Gal), N-acetylgalactosamine (GalNAc), N-
acetyl neuraminic acid (NeuNAc) and N-hydroxy-acetylneur-
aminic acid [25].3. Sialic acid/polysialic acid in the drug
delivery systems
In the history of drug delivery systems (DDS), carrier and drug
molecules PEGylated (PEGylation) technology is regarded as a
milestone. PEGylation nanoparticles can effectively reduce
the macrophage uptake in vitro, prolong the circulation half-
life in vivo and decrease the accumulation of nanoparticles
in liver and spleen. PEGylation can also improve the accu-
mulation of nanoparticles in tumor tissue by exerting the
enhanced permeability and retention (EPR) effect that is the
basis for delivering the macromolecular drugs to the site of
solid tumors selectively [26]. However, the PEG layer brings the
following three problems. 1) Cellular uptake blocked phe-
nomenon. The “cloud” of hydrophilic steric barrier plays a
crucial role in prolonging the residence time but it can
dramatically suppress their interaction with cells [27]. 2)
Accelerated blood clearance phenomenon. When repeated
injection, PEGylated carriers abundantly produce anti-PEG IgMand consequently enhance blood clearance because of anti-
PEG IgM mediating complement activation under certain
conditions. The phenomenon is called “accelerated blood
clearance (ABC)” [28]. 3) Security. PEG is difficult to degrade in
the body and accumulates in lysosomes, which can induce
toxicity and even a small amount of PEG oxidation products
in vivo is also harmful [29]. So ABC phenomenon and the
accumulation of PEGmay bring fairly serious consequences to
the body.
SA/PSAmay successfully solve the above problems [30]. As
an endogenous substances, SA can specifically bind to selec-
tin, which is highly expressed on tumor and endothelial cell
surface [4,6,12,31e34]. SA can transport the drug into the cell
by receptor-mediated endocytosis, which proves to be of high
specificity and strong affinity and increases the efficiency of
drug transportation and thus solves the problem of cellular
uptake blocked [35]. At the same time, PSA on the surfaces of
drugs/carriers will provide a “water cloudy” barrier, mainly
owing to its high hydrophilicity and chain flexibility. The
“cloud” protectsmodified drugs/carriers from interacting with
plasma proteins or macrophages, which causes less RES up-
take and prolongs the circulation half-life [10,11]. What is
more, antibody induced by 2e8 linked, shows a low level in the
blood, which indicates weak affinity and would not enhance
modified drugs/carriers clearance from the blood circulation.
Meanwhile, degradation products of SA/PSA are CO2 and
water that is non-toxic. Therefore, using SA/PSA as a non-
immunogenic and biodegradable new material, has the po-
tential of reducing or eliminating PEGylation preparation
inducing ABC phenomenon.
3.1. The modification of drug/carrier
3.1.1. The modification of small molecule drug
When modified by SA/PSA many excellent properties of SA/
PSA can be transferred to the coupling small molecules and
endow the conjugates with targeting, biocompatible and non-
toxic characteristics.
SA was covalently conjugated with PEG and DOX through a
critic acid spacer. Stability, spontaneous and esterase-
stimulated drug release was evaluated. More than 40% of
DOX was released from the conjugate in the presence of
esterase enzyme, whereas it was stable at pH 7.4. SA-PEG-
modified doxorubicin (DOX), PEG-DOX and free DOX were
incubated with A2780 ovarian cancer cells, respectively. It is
found that SA-conjugated DOX enhanced cytotoxicity when
compared with non-targeted prodrugs and free DOX [6].
The potential of polysialic acid (PSA) for low molecular
weight anti-cancer drugs also has been explored. A PSA-
epirubic (PSA-Epi) conjugate was synthesized and it was
compared against three other Epi conjugates, named: N-(2-
hydroxypropyl) methacrylamide copolymers (HPMA), poly(-
ethylene glycol) (PEG) and polyglutamic acid (PGA). In vitro
biological evaluation, which was conducted in the breast
cancer cell line MCF-7 and in the anthracycline resistant MCF-
7/DX, both showed that the PSA-Epi conjugate possessed the
highest activity. In vivo evaluation showed that all conjugates
had a significantly longer retention than free Epi [12].
This is the first study that PSA was used as a carrier to
conjugate with a low molecular drug. In this case, the study
Fig. 4 e The structure of Neu5Ac-PA.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 7 5e8 178illustrated the synthesis, characterization and biological
evaluation of the PSA-Epi. Meanwhile, the authors also carried
out a systematic comparison with those of the most common
drug carriers, aiming at obtaining some insight into the
impact of the polymeric carrier on the activity of an anti-
cancer drug conjugate.
3.1.2. The modification of protein
PSA is non-immunogenic, biodegradable, and can maintain
activity of the modifiers. Studies have pointed out that PSA-
asparaginase was non-immunogenic [11], and the activity of
the asparaginase almost remained, while after PEG modifica-
tion, its activity declined seriously [10]. Moreover, the PSA
modified protein/peptide eliminated immunogenicity and
antigenicity. At the same time, it also did not seem to influ-
ence their connectionwith the respective receptors [11]. PSA is
a human endogenous substance, which can be completely
degraded non-toxic SA by neuraminidase. However PEG is a
synthetic polymer, which generates ketone and aldehyde
groups by cytochrome P450 enzymes at a very low rate, and its
high/low molecular weight forms tend to accumulate in the
tissues [36]. When PEG was long-term injected, it would cause
accumulated toxicity. In this point of view, Gregoriadis
claimed that PSA is the best alternative to PEG [37]. PSA can
improve the pharmacokinetic properties of the drug and
reduce toxicity [38,39]. Currently a PSA modification indus-
trialization technology platform named PolyXen Technology
(Lipoxen PLC, London, UK) is commercially available, which
has been applied to insulin (SuliXen, clinical stage II), alfa2b-
interferon (InferoXen), granulocyte colony-stimulating fac-
tor (StimuXen) and erythropoietin (ErepoXen).
3.1.3. The modification of nanocarrier
To date, there are few reports on PSA-modified nanocarrier,
Bader et al. synthesized its derivatives in the preparation of
drug-loaded micelles. Carboxyl group of PSA reacted with n-
decylamine to produce PSAedecylamine derivative which
may self-assemble intomicelles thus load insoluble drugs [40].
The schematic was shown in Fig. 3. 3 years later, the same
laboratory alternated the hydrophobic end ODA with poly-
caprolactone (PCL). They found that the new derivative pre-
sented more stability and less cytotoxicity in vitro [41].
The first work applying GM1 modification to nanocarriers
was introduced by Gabizon and Papahadjopoulos [42]. After
intravenous injection in mice, it demonstrated that GM1-
modified liposomes reduced a 3.4-fold decrease in reticulo-
endothelial system (RES) uptake compared with conventional
liposomes (PC:Chol ¼ 10:5, w/w). Afterward, Liu et al. [43]
proved that GM1-modified liposomes could escape RESFig. 3 e The preparation of polysialic acid deuptake. After GM1 liposomes intravenously administered in
Balb/c mice, these liposomes were rapid uptake by the spleen
instead of liver Kupffer cells. The reason may be due to the
GM1 on the liposomes, which prolonged liposomes residence
time and then offered more chances to reach the spleen area.
To make a comparison of the long circulating effects pro-
moted by PEG and GM1, Maruyama et al. took DOX as a model
drug and prepared GM1 and PEG-modified liposomes. After
6 h, intravenously injection in DBA/2 mice, the drug concen-
trations in the bloodstream was 2.3-fold and 2.9-fold when
loaded with GM1 and PEG compared with conventional lipo-
somes, respectively. Meanwhile, GM1 and PEG-modified lipo-
some Blood/ERS uptake ratios were increased by 4.6-fold and
7.3-fold, respectively [44].
Neu5Ac-PA (Fig. 4) is a sialic acid derivative. The effects of
Neu5Ac-PA modified liposomes on the blood circulation and
tissue distribution was investigated comparedwith liposomes
composed of GM1. When liposomes were intravenously
administered in rats, the liver and spleen uptakes of lipo-
somes containing Neu5Ac-PA were significantly reduced
compared with those ones of liposomes containing GM1. The
plasma concentration of liposomes containing Neu5Ac-PA
was significantly greater than that of GM1 at all times and
was about as 10.3-fold as liposomes containing GM1 at 24 h
[45].
GM1 and Neu5Ac-PA are both sialic acid derivatives and
they have been used tomodify nanocarrier. Studies found that
the modified nanocarrier presented a longer residence time
and reduced uptake of RES. PSA modified nanocarriers have
been study little, but we believed that PSA can offer more
chances to receive the ideal residence time.
3.2. Targeting applications
3.2.1. Tumor targeting
SA can be served as a targeting ligand for selectin. Selectin is
highly expressed on tumor vascular endothelial cellscylamine derivatives and their micelles.
Fig. 5 e The structure of sialyl Lewis X.
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selectin ligand-1 (ESL-1), P-selectin glycoprotein ligand-1
(PSGL-1), glycosylation-dependent cell adhesion molecule-1
(GlyCAM-1), the surrounding lymph nodes addressin (PNAd),
CD24, CD34 and CD44 and so on. Nevertheless, sialyl Lewis A
(sLea) and sialyl Lewis X (sLex) are the smallest unit of the
known selectin ligands. At the same time, carboxyl group of
sialic acid on sLea/x is a functional group to identify selectin
indispensable [47]. The structure of sialyl Lewis X presented in
Fig. 5.
SA can be applied for cancer treatment mainly in two as-
pects. On the one hand, selectin serves as a target receptor.
People can make use of SA binding to selectin, which is
overexpressed on the surfaces of tumor cells. Afterward, SA
modified drugs/carriers are delivered to tumor cells, thus
achieving targeted therapeutic effects. Zheng et al. prepared
the selenium nanoparticles modified by SA to investigate the
targeting effects on human cervical carcinoma cells (HeLa).
In vitro showed that, compared with the general selenium
nanoparticles, SA modification could enhance cancer cell
uptake and induced apoptosis [48].
On the other hand, SA can be applied to inhibit tumor
metastasis. As is known to all, several cytokines produced by
tumor cells induce endothelial cells to express adhesion
molecules, such as selectin which mediates the adhesion of
malignant tumor cells to endothelium [49]. Selectin targeting
can inhibit cancer cell adhesion by competing with ligand-
bearing, and deliver anti-cancer drugs to tumor cells via
activated endothelial cells. Therefore, this kind of receptor
could prevent the adhesion and thereby inhibit metastasis.
sLex has been applied for inhibiting tumor cells adhesion with
endothelial cells. It is known [8] that E-selectin overexpressed
on tumor cells mediated tumor cells adhesion. Authors found
sLex-modified liposomes can inhibit tumor cells adhesion
with endothelial cells by competing with E-selectin.
SA seems to be an useful model in vitro for studies on site-
specific interactions and acts as an inhibitor in cancer
therapy.
3.2.2. Brain targeting
Studies have shown that the SA receptors exist in the brain
parenchymal, so brain targeting applications of SA were
explored. Bondioli and colleagues [50] synthesized SA-PLGA
and prepared the double covered (SA and glycopeptides)
nanoparticles, after intravenous injection in rats. They found
that therapeutical efficacy of loaded loperamide persisted for
more than 24 h, which presented a significant differencecomparedwithunmodifiednanoparticles.Thestudysuggested
that themodifiednanoparticlespassed through thebloodbrain
barrierwith thehelp of the glycopeptides on the surfaces. Then
owing to SA on the nanoparticle’ surfaces, the modified nano-
particles could interact with brain SA-specific receptors in the
brain parenchymal, thus brain residence time was extended
and loperamide gained an increased activity.
3.2.3. Lymphocyte targeting
Sunamoto et al. [51] demonstrated that SA involved in the
activation of lymphocytes, especially T cells. Meanwhile the
SA has been applied to the preparation of liposome vaccine.
Modified tumor surface antigen (TSAP) was incorporated in
liposome. After BALB mice were intravenously administrated
by liposomal vaccine, T lymphocytes were effectively acti-
vated and tumor growth was largely inhibited.
In the following research [52], TSAP was substituted with
ganglioside (GT1b or GQ1b) in liposome preparation, which
presented a more effective stimulation of T lymphocytes. The
authors suggested that the concentration of ganglioside on
the liposome surface was also crucial, demonstrating both the
number of SA groups and the position of the linkage on the
liposome play an important role in the activation of the T
lymphocytes. But the pathway that activated lymphocytes
mechanisms needs to be further explored.4. Conclusions
SA/PSA has shown specific advantages of tumor targeting,
cancer inhibition and stealth properties in the drug delivery
systems. At the same time, SA/PSA is non-immunogenic,
biocompatible and biodegradable, which can reduce or elim-
inate ABC phenomenon of PEGylation preparation to some
extent. However, SA receptors lie in other normal cells, tissues
and organs that will bring undesired problems. Hence, it is of
great significance to find SA/PSA appropriate modification
sites, change drugs/carriers linkage and optimize SA/PSA
modified density in the drug delivery systems.
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